Repligen | RGEN - Beneficio Operativo





Beneficio Operativo Cambio Fecha
Agilent USD 399M 46M 2026-03
Align Technology USD 191.32M 13.27M 2026-06
Bio Techne USD 75.49M 21.03M 2026-03
BioMarin Pharmaceutical USD 129.65M 68.74M 2026-03
Bristol-Myers Squibb USD 299M 3.07B 2026-06
Bruker USD 69.6M 59.4M 2026-06
Charles River Laboratories USD 119.9M 44.08M 2026-03
Danaher USD 1.13B 217M 2026-06
Dentsply International USD 32M 506M 2026-03
General Electric Aerospace USD 2.32B 549M 2026-03
Henry Schein USD 200M 18M 2026-06
Illumina USD 260M 21M 2026-06
IQVIA Holdings USD 2.6B 2.03B 2026-06
Mettler Toledo International USD 287.55M 53.61M 2026-06
Myriad Genetics USD -3M 20.3M 2025-12
OraSure Technologies USD -13.59M 2.13M 2025-12
Pacific Biosciences Of California USD -53.19M 35.08M 2025-12
Pfizer USD 667M 4.32B 2026-06
Repligen USD 21.13M 1.15M 2026-06
Revvity USD 126.14M 43.36M 2026-06
Standard Biotools USD -9.42M 12.51M 2026-03
Thermo Fisher Scientific USD 2.18B 273M 2026-06
Waters USD -86M 234M 2026-06
West Pharmaceutical Services USD 179.1M 2M 2026-06